Compass Point upgraded Hercules Capital from Neutral to Buy and set a new price target of $17.50
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/12/2024 | $19.50 → $21.50 | Mkt Perform → Outperform | Keefe Bruyette |
| 1/16/2024 | $17.00 → $17.50 | Buy → Neutral | Compass Point |
| 11/21/2023 | $17.00 | Neutral | UBS |
| 8/30/2023 | $17.50 | Neutral → Buy | Compass Point |
| 8/4/2023 | $13.50 → $17.00 | Underperform → Mkt Perform | Keefe Bruyette |
| 4/6/2023 | $16.00 | Neutral → Overweight | Piper Sandler |
| 3/13/2023 | $14.50 → $10.50 | Mkt Perform → Underperform | Keefe Bruyette |
| 7/29/2022 | Outperform → Perform | Oppenheimer |
CGM commercial operations to transition from Ascensia Diabetes Care to Senseonics Brian Hansen to be appointed Chief Commercial Officer Non-dilutive debt facility expanded up to $100 million with Hercules Capital to fund commercial organization Conference Call scheduled for September 4, 2025 at 8:00 A.M. Eastern Time GERMANTOWN, Md., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced a mutually executed Memorandum of Understanding to transition all commercialization and distributio
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that Kroll Bond Rating Agency, Inc. ("KBRA") has affirmed Hercules' investment grade corporate and credit rating of BBB+. KBRA issued a statement announcing the affirmation of the rating and stable outlook, as well as its underlying analysis. The affirmed BBB+ rating reflects the Company's diversified investment portfolio with a focus on senior secured first lien venture debt investments in the technology
CARY, N.C., Aug. 8, 2025 Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the completion of a comprehensive capital restructuring designed to enhance the Company's financial flexibility, reduce total debt, and support long-term growth. The multi-faceted refinancing transaction consisted of the following key components: A new senior credit facility with Hercules Capital, Inc. (NYSE:HTGC), due in 2030, which provides $110.0 million in committed capital at closing and an additional $40.0 million in two $20.0 million tranches available upon achievement of certain milestones, to be drawn at the Company's discretion;An exc
Keefe Bruyette upgraded Hercules Capital from Mkt Perform to Outperform and set a new price target of $21.50 from $19.50 previously
Compass Point downgraded Hercules Capital from Buy to Neutral and set a new price target of $17.50 from $17.00 previously
UBS initiated coverage of Hercules Capital with a rating of Neutral and set a new price target of $17.00
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
8-K - Hercules Capital, Inc. (0001280784) (Filer)
10-Q - Hercules Capital, Inc. (0001280784) (Filer)
SCHEDULE 13G/A - Hercules Capital, Inc. (0001280784) (Subject)
CGM commercial operations to transition from Ascensia Diabetes Care to Senseonics Brian Hansen to be appointed Chief Commercial Officer Non-dilutive debt facility expanded up to $100 million with Hercules Capital to fund commercial organization Conference Call scheduled for September 4, 2025 at 8:00 A.M. Eastern Time GERMANTOWN, Md., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced a mutually executed Memorandum of Understanding to transition all commercialization and distributio
CARY, N.C., Aug. 8, 2025 Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the completion of a comprehensive capital restructuring designed to enhance the Company's financial flexibility, reduce total debt, and support long-term growth. The multi-faceted refinancing transaction consisted of the following key components: A new senior credit facility with Hercules Capital, Inc. (NYSE:HTGC), due in 2030, which provides $110.0 million in committed capital at closing and an additional $40.0 million in two $20.0 million tranches available upon achievement of certain milestones, to be drawn at the Company's discretion;An exc
Q2 2025 Total Gross Debt and Equity Commitments of $1.0 Billion Record Q2 2025 Total Gross Fundings of $709.1 Million Record 1H 2025 Total Gross Debt and Equity Commitments of $2.02 Billion Record 1H 2025 Total Gross Fundings of $1.25 Billion Record Q2 2025 Net Investment Income "NII" of $88.7 Million Q2 2025 NII of $0.50 per Share provides 125% Coverage of the Base Cash Distribution Closed Upsized Offering of $350.0 Million of 6.000% Unsecured Notes due 2030 Renewed and Increased Its Credit Facility with MUFG Bank, Ltd. to $440.0 Million Conservative Balance Sheet Management with Net GAAP Leverage of 95.0% and Net Regulatory Leverage of 78.7%(1) Inclusive of the Adviser F
Strategic growth financing accelerates expansion through acquisition and supports product innovation Snappt, the leading platform for applicant trust in multifamily housing, today announced it has acquired Trigo, a company known for its breakthrough technology in verifying rental payment history. Backed by a $50 million committed facility from Hercules Capital, Inc. (NYSE:HTGC), the acquisition expands Snappt's platform and strengthens its ability to help property managers make faster, more confident leasing decisions. Together, these milestones mark a major step toward building the industry's most complete and trusted solution embedded into the application and screening process. "This
SAUSALITO, Calif., Nov. 29, 2023 /PRNewswire/ -- Revelation Partners, a healthcare investment firm with over $1.5 billion of capital under management, announced today the addition of Andrew Olson as Partner, Chief Financial Officer and Chief Operating Officer. Mr. Olson has an extensive background in the venture capital and funds management industry. His addition to the team will enhance the firm's technical expertise, support the differentiated investment model, and strengthen the firm's ongoing foundation. As the firm's new Chief Financial Officer and Chief Operating Officer
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that Nikos Theodosopoulos was appointed to serve as an independent member of its board of directors, effective September 21, 2023. Mr. Theodosopoulos is an experienced corporate executive and board director with more than 38 years in senior management roles in both the financial services and technology industries. Mr. Theodosopoulos will serve on the Company's Audit Committee. "Nikos' combined experienc
SC 13G - Hercules Capital, Inc. (0001280784) (Subject)
SC 13G/A - Hercules Capital, Inc. (0001280784) (Filed by)
SC 13G - Hercules Capital, Inc. (0001280784) (Filed by)